PE
BBIO icon

Point72 Europe’s BridgeBio Pharma BBIO Stock Holding History

Point72 Europe’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.65M Buy
+89,458
New +$4.36M 0.23% 94

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Europe's BBIO Position: Q3 2025 in Review

Point72 Europe opened a new position in BridgeBio Pharma (BBIO) in Q3 2025: 89,458 shares worth $4.65M. The stake represents 0.23% of the portfolio and ranks #94 among its holdings.

392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Point72 Europe held 89,458 shares of BridgeBio Pharma worth $4.65M as of Q3 2025.
  • BridgeBio Pharma was a new Point72 Europe position in Q3 2025.
  • BridgeBio Pharma made up 0.23% of Point72 Europe's portfolio in Q3 2025, its #94 holding.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.